Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine crossover study in multiple sclerosis-related fatigue and functional impairment
ACTRN12611000799954Phase 2Completed
- Sponsor
- University of New South Wales
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of dalfampridine in multiple sclerosis (MS) (2 arms), sponsored by University of New South Wales. Primary endpoint: Six-minute walk test. Started Aug 2011; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12611000799954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000799954.